Early Relief of Pruritus in Atopic Dermatitis with Crisaborole Ointment, A Non-steroidal, Phosphodiesterase 4 Inhibitor
Recommended Citation
Yosipovitch G, Stein Gold LF, Lebwohl MG, Silverberg JI, Tallman AM, Zane LT. Early Relief of Pruritus in Atopic Dermatitis with Crisaborole Ointment, A Non-steroidal, Phosphodiesterase 4 Inhibitor. Acta dermato-venereologica 2018; 98(5):484-489.
Document Type
Article
Publication Date
4-27-2018
Publication Title
Acta dermato-venereologica
Abstract
Pruritus occurs in all patients with atopic dermatitis and requires quick relief to reduce disease exacerbation and improve quality of life. Crisaborole ointment is a non-steroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate atopic dermatitis. This post hoc analysis explores crisaborole ointment for early relief of pruritus in patients with mild to moderate atopic dermatitis from 2 phase III studies. Patients received crisaborole or vehicle twice daily for 28 days. Pruritus was graded on a 4-point scale of none (0) to severe (3). Early improvement in pruritus required a score of none (0) or mild (1), with a ≥ 1-grade improvement from baseline on day 6. Significantly more patients experienced early improvement in pruritus with crisaborole than with vehicle (56.6% vs 39.5%; p< 0.001), including at earliest assessment (day 2, 34.3% vs 27.3%; p = 0.013). Crisaborole is a topical treatment option that can rapidly relieve atopic dermatitis-associated pruritus.
Medical Subject Headings
Administration, Cutaneous; Adolescent; Adult; Antipruritics; Boron Compounds; Child; Child, Preschool; Dermatitis, Atopic; Double-Blind Method; Female; Humans; Male; Ointments; Phosphodiesterase 4 Inhibitors; Pruritus; Remission Induction; Time Factors; Treatment Outcome
PubMed ID
29363715
Volume
98
Issue
5
First Page
484
Last Page
489
